<DOC>
	<DOC>NCT00618228</DOC>
	<brief_summary>The objective of this study was to assess bioequivalence of a potential generic 750 mg balsalazide disodium capsule formulation compared with Salix Pharmaceutical's 750 mg balsalazide disodium capsule, Colazal, following a single 750 mg dose, under fasting conditions.</brief_summary>
	<brief_title>Bioequivalency Study of Balsalazide Capsules Under Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Balsalazide</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>No clinically significant finding on the physical examination, medical history, or clinical laboratory results during screening. Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enyzme altering drugs. History of allergic or adverse response to balsalazide, mesalamine, salicylates, or other related drugs.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2008</verification_date>
</DOC>